The UK’s Cass Review on transgender care for young people led to the cessation of prescribing puberty blockers outside research protocols. In contrast, the US largely ignored the review’s findings, which called for a more holistic approach to care due to inadequate evidence on puberty blockers and hormones for gender-related distress. Some medical associations have defended current guidelines, while others have criticized the lack of scientific rigor. Public opinion on gender-affirming care remains divided, with some advocating for caution and others emphasizing the potential benefits. The review’s impact on American healthcare is expected to accelerate change despite ongoing debate.
Source link
UK review on gender medicine ‘largely ignored’ in the US, finds journalist
